SiteOne Therapeutics Announces Research and Development Agreement With Amgen to Advance Portfolio of Highly Selective, Potent Inhibitors of Naᵥ1.7 for Acute and Chronic Pain

SiteOne Announces the Concurrent Closing of its $15 Million Series B Round of Financing

Bozeman, Montana – SiteOne Therapeutics announced today the signing of a new research and development agreement with Amgen combining SiteOne’s experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen’s neuroscience capabilities.

Read More

Remembering George Miljanich, Ph.D, Founder & Chief Science Officer

he scientific achievements and warm memories of our friendships with George Miljanich live on with the team members and partners of SiteOne Therapeutics.

As a co-founder and Chief Scientific Officer of SiteOne Therapeutics, George brought more than 25 years of experience as an entrepreneur, inventor and scientist that empowered the people of SiteOne Therapeutics with an excellent foundation upon which to build. The seasoned leadership that George provided remains with the company every day as we move forward to help people struggling to more effectively treat acute and chronic pain with novel non-opioid based therapeutics.

Read More

SiteOne Therapeutics Secures Investment from Bozeman-based Next Frontier Capital

Company Continues to Build Presence in Bozeman, MT as it Advances its Portfolio of Highly Selective Naᵥ1.7 Inhibitors for the Treatment of Pain

BOZEMAN, MONTANA, July 15, 2015 — SiteOne Therapeutics Inc. today announced the completion of an investment by Next Frontier Capital, a newly created venture fund in Bozeman, Montana with a focus on local technology-based companies. Joining Next Frontier are 2M Companies Inc. and all of SiteOne’s current investors, including Sears Capital Management, Biobrit LLC, Mission Bay Capital and Z Investments. This investment further reflects SiteOne’s expanded presence in Bozeman, Montana as the company continues to advance its platform of non-opioid therapeutics for acute and chronic pain. In conjunction with the financing, Will Price, founder and managing partner of Next Frontier Capital, will join SiteOne’s board of directors.

Read More

SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant

Company Positioned to Advance Development of Novel Sodium Channel (Naᵥ) Inhibitors Targeting Pain

SAN FRANCISCO, Sept. 23, 2014 — SiteOne Therapeutics Inc. today announced the completion of its initial round of equity financing. Led by Sears Capital Management and Biobrit LLC, with additional investors Mission Bay Capital and Joe Zakrzewski, the $1.5 million financing positions SiteOne to advance its oral Naᵥ1.7 inhibitor program for pain and to further develop its technology platform for long-acting local analgesics, pain diagnostics and other pain indications.

Read More